Index - P/E - EPS (ttm) -3.41 Insider Own 21.79% Shs Outstand 15.09M Perf Week 20.20%
Market Cap 370.01M Forward P/E - EPS next Y -4.20 Insider Trans 21.83% Shs Float 11.80M Perf Month -10.97%
Income -64.47M PEG - EPS next Q -1.18 Inst Own 41.46% Short Float 4.17% Perf Quarter 103.82%
Sales 0.00M P/S - EPS this Y 21.47% Inst Trans 5.01% Short Ratio 4.29 Perf Half Y 257.80%
Book/sh 7.03 P/B 3.49 EPS next Y 13.51% ROA -89.35% Short Interest 0.49M Perf Year 87.18%
Cash/sh 5.76 P/C 4.26 EPS next 5Y - ROE -112.67% 52W Range 4.00 - 31.01 Perf YTD 210.77%
Dividend Est. - P/FCF - EPS past 5Y - ROI -80.33% 52W High -20.93% Beta 2.25
Dividend TTM - Quick Ratio 7.19 Sales past 5Y 0.00% Gross Margin - 52W Low 513.00% ATR (14) 1.81
Dividend Ex-Date - Current Ratio 7.19 EPS Y/Y TTM 39.99% Oper. Margin 0.00% RSI (14) 51.29 Volatility 7.14% 7.28%
Employees 45 Debt/Eq 0.04 Sales Y/Y TTM - Profit Margin - Recom 1.14 Target Price 67.50
Option/Short Yes / Yes LT Debt/Eq 0.02 EPS Q/Q -316.56% Payout - Rel Volume 0.51 Prev Close 23.98
Sales Surprise - EPS Surprise 6.76% Sales Q/Q - Earnings Mar 04 BMO Avg Volume 114.75K Price 24.52
SMA20 -0.91% SMA50 -2.48% SMA200 79.98% Trades
Volume 57,995 Change 2.25%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-03-24 Initiated Evercore ISI
Outperform
$65
Mar-28-24 Initiated RBC Capital Mkts
Outperform
$70
Mar-18-24 Initiated TD Cowen
Outperform
Aug-11-23 Initiated CapitalOne
Overweight
$7
Feb-28-22 Initiated Cantor Fitzgerald
Overweight
$10
Nov-08-21 Initiated Credit Suisse
Outperform
$15
Oct-21-21 Initiated William Blair
Outperform
Oct-20-21 Initiated BMO Capital Markets
Outperform
$19
Oct-13-21 Initiated Oppenheimer
Outperform
$21
Apr-02-24 04:30PM
Mar-22-24 08:50AM
Mar-21-24 04:30PM
Mar-19-24 08:00AM
Mar-15-24 08:00AM
12:00PM
Loading…
Mar-14-24 12:00PM
Mar-06-24 12:53PM
08:50AM
Mar-04-24 07:30AM
Feb-26-24 04:30PM
Feb-23-24 08:00AM
Feb-19-24 08:50AM
Feb-07-24 08:00AM
Feb-06-24 08:59AM
Feb-05-24 08:00AM
08:00AM
Loading…
Feb-02-24 08:00AM
Jan-24-24 12:14PM
Jan-05-24 08:30AM
Jan-02-24 08:00AM
Dec-18-23 04:30PM
Dec-10-23 11:00AM
Nov-30-23 08:00AM
Nov-09-23 09:48AM
08:00AM
Nov-08-23 04:30PM
Nov-02-23 09:00AM
Nov-01-23 08:00AM
Oct-09-23 08:30AM
08:00AM
Sep-25-23 08:00AM
08:00AM
Loading…
Sep-21-23 08:00AM
Sep-15-23 08:00AM
Aug-11-23 04:05PM
Aug-04-23 04:51PM
Aug-02-23 08:00AM
Jun-22-23 08:00AM
Jun-20-23 08:00AM
Jun-13-23 08:00AM
May-12-23 04:05PM
May-10-23 08:00AM
Apr-13-23 08:00AM
Apr-10-23 04:05PM
Mar-31-23 08:00AM
Mar-23-23 08:00AM
Mar-09-23 08:00AM
Mar-08-23 04:05PM
Feb-17-23 08:20AM
08:10AM
08:00AM
Feb-16-23 04:05PM
Feb-03-23 04:05PM
Jan-30-23 08:00AM
Jan-27-23 01:10PM
Jan-25-23 08:00AM
Jan-24-23 04:25PM
Jan-13-23 08:00AM
Jan-10-23 08:00AM
Jan-04-23 08:00AM
Jan-03-23 08:00AM
Nov-10-22 04:05PM
Sep-26-22 08:00AM
Sep-23-22 08:00AM
Sep-15-22 08:00AM
Aug-12-22 04:05PM
Jun-23-22 04:05PM
Jun-20-22 10:59AM
Jun-07-22 08:00AM
Jun-06-22 08:00AM
May-27-22 08:00AM
(American City Business Journals)
May-17-22 08:00AM
May-12-22 04:05PM
Apr-28-22 08:00AM
Apr-26-22 04:05PM
Apr-22-22 08:00AM
Mar-31-22 08:00AM
Mar-25-22 07:30PM
Mar-21-22 08:30AM
Mar-18-22 04:05PM
Mar-10-22 08:00AM
Feb-28-22 08:00AM
Feb-24-22 05:19PM
Feb-02-22 01:38PM
Dec-08-21 11:15AM
08:30AM
Nov-20-21 08:21AM
Nov-12-21 04:05PM
Nov-09-21 08:00AM
Nov-08-21 08:00AM
Oct-15-21 09:39PM
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in enabling cures through hematopoietic stem cell therapy. It focuses on the development and commercialization of safer, stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company was founded by Judith Shizuru and Susan Prohaska in March 2018 and is headquartered in Redwood City, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Mahal Jeetinder Singh Chief Operating Officer Mar 12 '24 Option Exercise 7.10 900 6,390 25,909 Mar 12 09:33 PM Mahal Jeetinder Singh Chief Operating Officer Mar 12 '24 Sale 26.44 900 23,792 25,009 Mar 12 09:33 PM Velan Capital Investment Manag 10% Owner Feb 08 '24 Buy 12.95 350,000 4,532,500 1,188,500 Feb 09 08:40 PM Carlyle Group Inc. Former 10% Owner Feb 08 '24 Buy 12.95 190,000 2,460,500 1,066,189 Feb 12 06:23 PM WIGGANS THOMAS G Director Nov 28 '23 Buy 0.65 10,000 6,486 50,000 Nov 30 04:05 PM WIGGANS THOMAS G Director Nov 21 '23 Buy 0.64 10,000 6,383 40,000 Nov 22 04:06 PM WIGGANS THOMAS G Director Nov 20 '23 Buy 0.63 10,000 6,309 30,000 Nov 20 08:14 PM WIGGANS THOMAS G Director Nov 17 '23 Buy 0.60 10,000 5,966 20,000 Nov 20 08:14 PM WIGGANS THOMAS G Director Nov 16 '23 Buy 0.60 10,000 5,965 10,000 Nov 20 08:14 PM Lis William Director Oct 13 '23 Sale 0.85 7,965 6,777 53,521 Oct 13 06:56 PM Mahal Jeetinder Singh See Remarks Jun 13 '23 Option Exercise 0.71 9,000 6,390 296,223 Jun 13 08:54 PM Mahal Jeetinder Singh See Remarks Jun 13 '23 Sale 1.66 9,000 14,915 287,223 Jun 13 08:54 PM
Index - P/E - EPS (ttm) -3.46 Insider Own 0.54% Shs Outstand 98.72M Perf Week 2.14%
Market Cap 1.60B Forward P/E - EPS next Y -1.39 Insider Trans -9.35% Shs Float 98.19M Perf Month 5.18%
Income -334.62M PEG - EPS next Q -0.51 Inst Own 42.01% Short Float 4.15% Perf Quarter -27.78%
Sales 266.72M P/S 6.01 EPS this Y 7.60% Inst Trans -2.02% Short Ratio 6.35 Perf Half Y -34.34%
Book/sh 8.19 P/B 1.98 EPS next Y 56.67% ROA -29.66% Short Interest 4.08M Perf Year -52.16%
Cash/sh 8.17 P/C 1.99 EPS next 5Y - ROE -36.34% 52W Range 13.48 - 39.50 Perf YTD -40.54%
Dividend Est. - P/FCF - EPS past 5Y -16.93% ROI -41.61% 52W High -58.86% Beta 1.13
Dividend TTM - Quick Ratio 4.41 Sales past 5Y 2095.12% Gross Margin 64.08% 52W Low 20.55% ATR (14) 0.81
Dividend Ex-Date - Current Ratio 4.63 EPS Y/Y TTM 25.17% Oper. Margin -141.19% RSI (14) 52.69 Volatility 5.21% 4.46%
Employees 2175 Debt/Eq 0.02 Sales Y/Y TTM 24.03% Profit Margin -125.46% Recom 1.15 Target Price 51.69
Option/Short Yes / Yes LT Debt/Eq 0.01 EPS Q/Q -52.98% Payout - Rel Volume 0.46 Prev Close 16.59
Sales Surprise -8.76% EPS Surprise -90.47% Sales Q/Q 5.16% Earnings May 08 AMC Avg Volume 641.76K Price 16.25
SMA20 6.83% SMA50 -5.64% SMA200 -30.56% Trades
Volume 293,029 Change -2.05%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-14-23 Initiated Morgan Stanley
Overweight
$47.50
Aug-10-23 Initiated Cantor Fitzgerald
Overweight
$70
Jan-21-22 Initiated Macquarie
Outperform
$64
Oct-12-21 Initiated Bernstein
Mkt Perform
Apr-28-20 Initiated Goldman
Buy
Apr-15-20 Initiated Guggenheim
Buy
$75
Jul-12-19 Initiated BofA/Merrill
Buy
Jul-05-19 Initiated Macquarie
Outperform
Jan-29-19 Initiated Credit Suisse
Outperform
Nov-21-18 Initiated Jefferies
Buy
Jun-21-18 Resumed Leerink Partners
Outperform
$43
Feb-14-18 Upgrade JP Morgan
Neutral → Overweight
Oct-16-17 Initiated Leerink Partners
Outperform
$42
Oct-16-17 Initiated JP Morgan
Neutral
$32
Show Previous Ratings
Apr-15-24 07:30AM
Apr-11-24 07:30AM
Apr-02-24 07:30AM
Apr-01-24 07:30AM
Mar-27-24 09:29AM
04:30PM
Loading…
Mar-20-24 04:30PM
Mar-19-24 07:01PM
Mar-13-24 07:05PM
Mar-06-24 04:01PM
07:30AM
Mar-01-24 10:12AM
Feb-29-24 08:51AM
Feb-27-24 04:38PM
04:05PM
Feb-25-24 09:32PM
04:15PM
Loading…
Jan-25-24 04:15PM
Jan-10-24 05:12PM
Jan-04-24 07:02PM
Dec-22-23 12:00PM
Dec-19-23 07:30AM
Dec-13-23 08:53AM
Dec-12-23 11:10PM
Nov-23-23 09:42AM
Nov-09-23 02:39PM
Nov-07-23 04:05PM
Oct-26-23 07:30AM
Oct-18-23 07:30AM
Oct-17-23 08:25AM
Oct-14-23 01:15PM
Sep-21-23 04:48PM
07:30AM
Loading…
Sep-18-23 07:30AM
Sep-05-23 11:16AM
09:23AM
Aug-31-23 09:16AM
Aug-30-23 07:30AM
Aug-29-23 07:38AM
Aug-10-23 10:12AM
Aug-07-23 04:05PM
Jul-28-23 03:57PM
Jul-20-23 07:30AM
Jul-19-23 07:30AM
Jul-17-23 01:03AM
Jul-14-23 07:30AM
Jul-10-23 07:30AM
Jul-06-23 04:05PM
Jun-30-23 11:20AM
09:22AM
Jun-28-23 07:30AM
Jun-12-23 08:56AM
Jun-07-23 11:05AM
Jun-06-23 08:05AM
Jun-01-23 04:03PM
May-25-23 07:30AM
May-24-23 08:01AM
May-22-23 11:11AM
May-18-23 07:30AM
May-15-23 02:57PM
May-10-23 11:53AM
May-09-23 04:01PM
May-03-23 09:58PM
Apr-27-23 07:30AM
Apr-26-23 10:25AM
Apr-20-23 07:30AM
Apr-18-23 01:55PM
Apr-14-23 03:32AM
Apr-11-23 08:03AM
Mar-26-23 07:45AM
Mar-20-23 06:35AM
Mar-17-23 07:19AM
06:59AM
Mar-10-23 06:55AM
Mar-08-23 09:06AM
Mar-06-23 09:55AM
08:30AM
Mar-03-23 12:55PM
Mar-01-23 04:01PM
Feb-28-23 07:30AM
Feb-22-23 04:30PM
07:30AM
Feb-09-23 07:30AM
Feb-07-23 05:36AM
Jan-31-23 07:30AM
Jan-30-23 07:30AM
Jan-27-23 02:56PM
(Investor's Business Daily)
Jan-18-23 07:49AM
Jan-16-23 02:18AM
Jan-09-23 07:30AM
Jan-05-23 03:50PM
10:21AM
10:19AM
08:57AM
07:34AM
Jan-03-23 08:30AM
Jan-01-23 08:13AM
Dec-20-22 07:30AM
Dec-19-22 08:38AM
Dec-15-22 04:05PM
Dec-05-22 06:10PM
Nov-12-22 08:05AM
Nov-09-22 04:01PM
Zai Lab Ltd. is a biopharmaceutical company, which engages in the developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience. Its products include Zejula, Optune, Qinlock, and Nuzyra. The company was founded by Samantha Ying Du and Marietta Wu in April 2014 and is headquartered in Shanghai, China.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Reinhart Harald See Remarks Apr 04 '24 Sale 15.67 2,105 32,992 51,800 Apr 05 05:48 PM Smiley Joshua L See Remarks Apr 04 '24 Sale 15.67 1,988 31,158 28,684 Apr 05 05:48 PM Amado Rafael See Remarks Apr 04 '24 Sale 15.67 1,952 30,594 23,532 Apr 05 05:47 PM Edmondson Frazor Titus III Chief Legal Officer Apr 04 '24 Sale 15.67 1,244 19,497 26,408 Apr 05 05:48 PM Chen Yajing Chief Financial Officer Apr 04 '24 Sale 15.67 845 13,244 9,618 Apr 05 05:47 PM Smiley Joshua L See Remarks Apr 03 '24 Option Exercise 15.90 7,145 113,606 30,672 Apr 05 05:48 PM Amado Rafael See Remarks Apr 03 '24 Option Exercise 15.90 5,391 85,717 25,484 Apr 05 05:47 PM Reinhart Harald See Remarks Apr 03 '24 Option Exercise 15.90 5,270 83,793 53,905 Apr 05 05:48 PM Edmondson Frazor Titus III Chief Legal Officer Apr 03 '24 Option Exercise 15.90 5,031 79,993 27,652 Apr 05 05:48 PM Chen Yajing Chief Financial Officer Apr 03 '24 Option Exercise 15.90 2,500 39,750 10,463 Apr 05 05:47 PM Du Ying Chairperson & CEO Apr 02 '24 Sale 16.15 5,787 93,466 1,107,972 Apr 03 09:44 PM Reinhart Harald See Remarks Apr 02 '24 Sale 16.15 1,773 28,636 48,635 Apr 03 09:45 PM Edmondson Frazor Titus III Chief Legal Officer Apr 02 '24 Sale 16.15 885 14,294 22,621 Apr 03 09:54 PM Chen Yajing Chief Financial Officer Apr 02 '24 Sale 16.15 519 8,382 7,963 Apr 03 09:44 PM Du Ying Chairperson & CEO Apr 01 '24 Option Exercise 16.72 14,200 237,424 1,113,759 Apr 03 09:44 PM Reinhart Harald See Remarks Apr 01 '24 Option Exercise 16.72 4,348 72,699 50,408 Apr 03 09:45 PM Edmondson Frazor Titus III Chief Legal Officer Apr 01 '24 Option Exercise 16.72 3,501 58,537 23,506 Apr 03 09:54 PM Chen Yajing Chief Financial Officer Apr 01 '24 Option Exercise 16.72 1,500 25,080 8,482 Apr 03 09:44 PM Edmondson Frazor Titus III Chief Legal Officer Mar 15 '24 Sale 18.71 10,000 187,127 20,005 Mar 19 04:12 PM Amado Rafael See Remarks Mar 15 '24 Sale 18.86 2,544 47,980 20,093 Mar 19 04:12 PM Smiley Joshua L See Remarks Mar 01 '24 Buy 20.83 3,000 62,490 23,527 Mar 04 04:28 PM Du Ying Chairperson & CEO Jan 03 '24 Sale 26.12 8,380 218,902 1,133,450 Jan 03 07:25 PM Edmondson Frazor Titus III Chief Legal Officer Jan 03 '24 Sale 26.12 4,803 125,464 30,005 Jan 03 07:25 PM Reinhart Harald See Remarks Jan 03 '24 Sale 26.12 4,803 125,464 46,060 Jan 03 07:25 PM Amado Rafael See Remarks Jan 02 '24 Sale 26.30 19,363 509,169 22,637 Jan 03 07:26 PM Smiley Joshua L See Remarks Dec 14 '23 Buy 29.90 4,000 119,600 20,527 Dec 18 05:08 PM Smiley Joshua L See Remarks Nov 16 '23 Buy 26.93 5,000 134,650 16,527 Nov 16 06:04 PM Chen Yajing Chief Financial Officer Nov 02 '23 Sale 25.23 165 4,163 6,982 Nov 03 04:44 PM Du Ying Chairperson & CEO Jun 23 '23 Option Exercise 25.30 58,800 1,487,640 1,055,913 Jun 26 04:06 PM Reinhart Harald See Remarks Jun 23 '23 Option Exercise 25.30 18,250 461,725 40,497 Jun 26 04:07 PM Edmondson Frazor Titus III Chief Legal Officer Jun 23 '23 Option Exercise 25.30 14,600 369,380 36,547 Jun 26 04:05 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
